Solabegron Impurities

Solabegron (code name GW-427,353) is a drug which acts as a selective agonist for the β3 adrenergic receptor. It is being developed for the treatment of overactive bladder and irritable bowel syndrome. It has been shown to produce visceral analgesia by receptor-mediated attenuation of afferent nociceptive signaling and by relaxing detrusor and visceral smooth muscle through Gs protein coupling that raises intracellular cAMP, reducing spontaneous contractions and sensory hypersensitivity. In vitro pharmacology demonstrates pronounced β3 versus β1 and β2 selectivity, while preclinical efficacy shows dose-dependent increases in bladder capacity and reductions in visceral pain responses. Clinical pharmacokinetic properties include oral absorption with a profile supporting once- or twice-daily dosing, primary hepatic metabolism with identifiable oxidative and conjugative pathways, and a plasma elimination half-life compatible with sustained receptor occupancy. Safety assessments in development have focused on cardiovascular selectivity, CYP interaction potential, and tolerability in target populations.